DNAtriX is a biotechnology company that develops and commercializes virus-driven immunotherapies for the treatment of cancer... Read more
DNAtriX is a biotechnology company that develops and commercializes virus-driven immunotherapies for the treatment of cancer... Read more
News
Nov 22, 2021
Markets Insider
DNAtrix: DNAtrix Announces Oral Presentation of Positive Overall Survival Data with DNX-2401 in DIPG at the Society for Neuro-oncology (SNO) Annual Meeting
Jun 09, 2021
Markets Insider
DNAtrix: DNAtrix to Present at the Raymond James Human Health Innovations Conference
Mar 04, 2021
PR Newswire
Press Release: DNAtrix : DNAtrix Announces First Patient Dosed in Clinical Study of DNX-2440, an OX40 Ligand Expressing Immunotherapy, in Colorectal Cancer and Other Cancers with Liver Metastasis
Feb 11, 2021
PR Newswire
Press Release: DNAtrix : DNAtrix Announces Preclinical Data Demonstrating Anti-Tumor Activity of DNX-2401 in Models of Pediatric Tumors (AT/RT and CNS-PNET) Published in Clinical Cancer Research
Nov 20, 2020
PR Newswire
Press Release: DNAtrix : DNAtrix Announces Positive Data from Phase 2 CAPTIVE (KEYNOTE-192) Study with DNX-2401 in Patients with Recurrent Glioblastoma Highlighted in an Oral Late-Breaking Presentation During Society for Neuro-oncology (SNO) Annual Meeting
Nov 09, 2020
PR Newswire
Press Release: DNAtrix : DNAtrix Announces Multiple Data Presentations, Including Late-Breaking Phase 2 CAPTIVE (KEYNOTE-192) Data in Recurrent Glioblastoma, Planned for the Society for Neuro-oncology (SNO) Annual Meeting
Jan 14, 2020
Post Online Media
DNAtrix: DNAtrix appoints Jeffrey Knapp as chief executive officer
Nov 24, 2019
StreetInsider
Press Release: DNAtrix : DNAtrix Presents Positive Results from the Phase 2 CAPTIVE/KEYNOTE-192 Study of DNX-2401 in Combination with Pembrolizumab for Glioblastoma at the 2019 SNO Annual Meeting
Nov 26, 2018
PharmiWeb
DNAtrix: DNAtrix's Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial
Nov 25, 2018
BioPortfolio
DNAtrix: DNAtrix Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13082018 Prices from USD $250
DNAtrix Competitors
1
2
3
4
5
6
7
8
9
10